CRF (6-33)CRF-binding protein inhibitor CAS# 120066-38-8 |
2D Structure
- Regorafenib monohydrate
Catalog No.:BCC1884
CAS No.:1019206-88-2
- CP-673451
Catalog No.:BCC4981
CAS No.:343787-29-1
- Regorafenib
Catalog No.:BCC3646
CAS No.:755037-03-7
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
- Tie2 kinase inhibitor
Catalog No.:BCC2561
CAS No.:948557-43-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 120066-38-8 | SDF | Download SDF |
PubChem ID | 71308685 | Appearance | Powder |
Formula | C141H231N41O43S | M.Wt | 3220.68 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Corticotropin-Releasing Factor (6-33) | ||
Solubility | Soluble to 1 mg/ml in water | ||
Sequence | ISLDLTFHLLREVLEMARAEQLAQQAHS | ||
SMILES | CCC(C)C(C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCSC)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(C)C(=O)NC(CC3=CNC=N3)C(=O)NC(CO)C(=O)O)N | ||
Standard InChIKey | XHHPINGDTRCKNN-QZXFXOMNSA-N | ||
Standard InChI | InChI=1S/C141H231N41O43S/c1-23-72(16)109(145)136(221)179-100(61-183)135(220)174-93(52-68(8)9)129(214)176-99(58-108(195)196)133(218)173-95(54-70(12)13)134(219)182-111(77(21)185)138(223)178-96(55-78-29-25-24-26-30-78)130(215)175-98(57-80-60-151-64-155-80)131(216)172-92(51-67(6)7)128(213)171-91(50-66(4)5)126(211)163-82(32-28-47-153-141(148)149)119(204)166-88(38-44-107(193)194)124(209)181-110(71(14)15)137(222)177-94(53-69(10)11)127(212)167-87(37-43-106(191)192)122(207)168-89(45-48-226-22)118(203)158-73(17)112(197)160-81(31-27-46-152-140(146)147)116(201)156-74(18)113(198)162-86(36-42-105(189)190)121(206)165-85(35-41-104(144)188)123(208)170-90(49-65(2)3)125(210)159-75(19)114(199)161-84(34-40-103(143)187)120(205)164-83(33-39-102(142)186)117(202)157-76(20)115(200)169-97(56-79-59-150-63-154-79)132(217)180-101(62-184)139(224)225/h24-26,29-30,59-60,63-77,81-101,109-111,183-185H,23,27-28,31-58,61-62,145H2,1-22H3,(H2,142,186)(H2,143,187)(H2,144,188)(H,150,154)(H,151,155)(H,156,201)(H,157,202)(H,158,203)(H,159,210)(H,160,197)(H,161,199)(H,162,198)(H,163,211)(H,164,205)(H,165,206)(H,166,204)(H,167,212)(H,168,207)(H,169,200)(H,170,208)(H,171,213)(H,172,216)(H,173,218)(H,174,220)(H,175,215)(H,176,214)(H,177,222)(H,178,223)(H,179,221)(H,180,217)(H,181,209)(H,182,219)(H,189,190)(H,191,192)(H,193,194)(H,195,196)(H,224,225)(H4,146,147,152)(H4,148,149,153)/t72-,73-,74-,75-,76-,77+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,109-,110-,111-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Corticotropin-releasing factor binding protein (CRFBP) inhibitor peptide; displaces CRF from CRFBP. Suppresses body weight gain and increases motor activity in obese rats in vivo. |
CRF (6-33) Dilution Calculator
CRF (6-33) Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Shizukanolide F
Catalog No.:BCN6411
CAS No.:120061-96-3
- Meridinol
Catalog No.:BCN6087
CAS No.:120051-54-9
- Edgeworin
Catalog No.:BCN6561
CAS No.:120028-43-5
- VCH-916
Catalog No.:BCC2031
CAS No.:1200133-34-1
- Donepezil HCl
Catalog No.:BCC4569
CAS No.:120011-70-3
- Dichlorphenamide
Catalog No.:BCC3761
CAS No.:120-97-8
- 1,2-Benzenediol
Catalog No.:BCN6103
CAS No.:120-80-9
- N,N'-Bis(salicylidene)-1,3-propanediamine
Catalog No.:BCC9063
CAS No.:120-70-7
- 2'-Methylacetanilide
Catalog No.:BCC8581
CAS No.:120-66-1
- Isosafrole
Catalog No.:BCC3976
CAS No.:120-58-1
- Benzyl benzoate
Catalog No.:BCN8521
CAS No.:120-51-4
- Ethylparaben
Catalog No.:BCN6094
CAS No.:120-47-8
- Fmoc-D-Arg(Mtr)-OH
Catalog No.:BCC3078
CAS No.:120075-24-3
- Flavanthrin
Catalog No.:BCN3687
CAS No.:120090-80-4
- IPI-145 (INK1197)
Catalog No.:BCC1104
CAS No.:1201438-56-3
- Crotaleschenine
Catalog No.:BCN2077
CAS No.:120154-95-2
- Vinflunine Tartrate
Catalog No.:BCC4602
CAS No.:1201898-17-0
- MLN9708
Catalog No.:BCC2091
CAS No.:1201902-80-8
- TCS 2210
Catalog No.:BCC7798
CAS No.:1201916-31-5
- Cynoglossamine
Catalog No.:BCN1970
CAS No.:120193-39-7
- 3,4-Dihydroxycinnamamide
Catalog No.:BCN6090
CAS No.:1202-41-1
- Clopidogrel
Catalog No.:BCC2497
CAS No.:120202-66-6
- Clopidogrel Related Compound C
Catalog No.:BCN2689
CAS No.:120202-71-3
- NMS-P715
Catalog No.:BCC6373
CAS No.:1202055-34-2
oCRF and CRF (6-33) depress food but not water intake in the obese Zucker rat.[Pubmed:10997635]
Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S140-1.
It has previously been demonstrated that oCRF and the CRF binding protein inhibitor CRF (6-33) reduce body-weight gain in obese Zucker rats. We investigated whether the reduction in body-weight is attributable to altered feeding and drinking behaviour. Obese Zucker rats were fitted with osmotic mini-pumps connected to i.c.v. cannulas. Vehicle, oCRF (5 microg/day) or CRF (6-33) (25 microg/day) were infused for 7 days and the animals observed for an additional 7 days. Body-weight and food and water-intake were recorded daily at 14.00 h. In agreement with published results, oCRF and CRF (6-33) significantly reduced body-weight gain in the obese Zucker rat. In addition, food intake was reduced, whereas water consumption was unaffected.
The binding protein of corticotropin-releasing factor: ligand-binding site and subunit structure.[Pubmed:12215497]
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12055-60.
Corticotropin-releasing factor (CRF), recognized as an important stress factor, binds to a CRF receptor and a CRF-binding protein (CRFBP) that represents a reservoir of endogenous CRF. Although CRFBP was observed to dimerize, at least in part, the ligand was found to be exclusively bound to the monomer-as indicated by photoaffinity labeling. We localized the CRF binding site by using photoaffinity labeling in combination with different mass spectrometric techniques. The amino acid residues Arg-23 and Arg-36 of CRFBP were identified as the sites of photoincorporation of monofunctional and bifunctional photoprobes designed on the basis of the amino acid sequence of human/rat CRF(6-33). It was, therefore, concluded that the sequence of amino acid residues 23-36 of CRFBP is involved in ligand binding. Our data are in support of an antiparallel alignment of the photoprobe with the amino acid residues 23-36 of the CRFBP monomer.
Dissociation of arousal-like from anxiogenic-like actions of brain corticotropin-releasing factor receptor ligands in rats.[Pubmed:11287075]
Behav Brain Res. 2001 Jul;122(1):43-50.
Behavioral actions of centrally administered corticotropin-releasing factor (CRF) are likely subserved by multiple brain targets and functional effector systems. The present studies compared effects of two CRF ligands, a full, post-synaptic CRF receptor agonist (rat/human CRF(1-41)) and a CRF binding protein ligand inhibitor (rat/human CRF(6-33)) in a behavioral testing battery sensitive to arousal, fear-like and aversive processes in Wistar rats. The profile of global efficacy for the centrally administered CRF receptor agonist was characterized by low dose (0.5-1.0 microg) arousal-like effects in locomotor and conditioned ambulation contexts and by high dose (5-25 microg) conditioned immobility, taste aversion and place aversion. In contrast, a profile of limited efficacy for the centrally administered CRF binding protein ligand inhibitor included only dose dependent motor activating and facilitation of fear conditioning effects without any of the anxiogenic-like or aversive properties of CRF agonist administration. These results suggest that arousal-like activation is a fundamental, physiologically relevant consequence of brain CRF system stimulation whereas aversive and anxiety-like effects reflect pharmacological actions of a CRF receptor agonist.
Selective stimulatory actions of corticotropin-releasing factor ligands on correlates of energy balance.[Pubmed:11564446]
Physiol Behav. 2001 Sep 1-15;74(1-2):5-13.
Acute administration of corticotropin-releasing factor (CRF) results in anorexic and sympathomimetic effects that suggest efficacy in chronic models of energy balance. The present studies employed a broad spectrum energy balance indices in lean and genetically obese Zucker rats in order to fully characterize the pharmacological efficacy of CRF and a CRF binding protein (CRF-BP) ligand inhibitor, CRF(6-33), which is thought to liberate CRF from CRF-BP. Acute administration of CRF(6-33) significantly increased CRF(2) receptor density by 10% within the ventromedial hypothalamic (VMH) nucleus of Zucker lean rats and decreased density by 10% in Zucker obese rats. A single infusion of CRF(6-33) increased nonshivering thermogenesis by 25-30% as measured by proton conductance in brown adipose tissue of both lean and obese rats. Chronic CRF(6-33) infusion suppressed body weight gain and elevated core temperature irrespective of genotype while increasing motor activity in obese rats without altering heart rate or blood pressure. Taken together, these results document strain-dependent, long-term effects of a CRF-BP ligand inhibitor on a select subset of physiological and behavioral measures of increased energy expenditure.